德国拜耳利伐沙班的治疗效果

Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. Rivaroxaban was jointly developed by Bayer Pharma of Germany and Johnson & Johnson of the United States. In October 2008, Rivaroxaban was approved for marketing in Canada and the European Union.

Indications for Rivaroxaban include: for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery; for the treatment of venous thrombosis (DVT) in adults to reduce DVT recurrence and pulmonary disease after acute DVT. Risk of Embolism (PE); for use in adult patients with nonvalvular atrial fibrillation and who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Bayer is headquartered in Leverkusen, Germany. Polymers, pharmaceuticals and health care, chemicals and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types. The company has produced aspirin, heroin, Rivaroxaban and other products.

Therapeutic effect of Bayer's rivaroxaban in Germany: EINSTEIN-Jr is a randomized, open-label phase III study that enrolled 500 pediatric patients (birth to 17 years old) who were diagnosed with acute VTE and started receiving heparin therapy. Pediatric patients received open-label, weight-adjusted dose rivaroxaban or standard anticoagulation in a 2:1 ratio.

The treatment period is 3 months, except for children under 2 years of age with catheter-related VTE who receive 1 month of treatment. Repeat imaging was performed at the end of treatment. The results showed that the study met all prespecified endpoints: recurrent VTE events were similar in the two groups, slightly lower in the Rivaroxaban treatment group, and there were no fatal VTE events in either treatment group.

The above is the introduction about Rivaroxaban. If patients have other questions about rivaroxaban (such as drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/90000.html